Targeted Medical Pharma Appoints Dr. David Silver as President and COO

Targeted Medical Pharma Appoints Dr. David Silver as President and COO

LOS ANGELES--(BUSINESS WIRE)-- Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced the promotion of David Silver, M.D., to the newly created position of president and chief operating officer, where he will oversee the company's expansion efforts and daily operations, while continuing his responsibilities as executive vice president of medical and scientific affairs.

"Dr. Silver has been an integral part of our organization since giving up his private practice two years ago to join us full time," said William Shell, M.D, the company's CEO and chief scientific officer. "He has been instrumental in helping us reach this important inflection point. His strong leadership skills will be leveraged as we work to expand our sales force, bringing our prescription-only medical foods to patients and physicians across the United States."

Dr. Silver has conducted more than 100 clinical trials and is a national expert on pain, fibromyalgia and rheumatologic diseases. He is a practicing board-certified rheumatologist and internist, and served as clinical chief of rheumatology and director of the chronic pain rehabilitation program at Cedars Sinai Medical Center in Los Angeles. Dr. Silver remains active in academia as an associate clinical professor of medicine at UCLA. He received a Bachelor of Arts degree in medical sciences with a minor in economics from Boston University. After earning a medical degree from Boston University's School of Medicine, he completed his residency in Internal Medicine at Northwestern University's School of Medicine, with a fellowship in Rheumatology at Cedars Sinai Medical Center.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company's subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides a billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press releasemay contain forward-looking statements related to the company's business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Investor Contacts:
ProActive Capital Group
Jeff Ramson, Founder & CEO
ramson@proactivecapital.com
646-863-6893
or
Media Contacts:
PondelWilkinson
George Medici gmedici@pondel.com
Ron Neal rneal@pondel.com
310-279-5980

KEYWORDS: United States North America California

INDUSTRY KEYWORDS:

The article Targeted Medical Pharma Appoints Dr. David Silver as President and COO originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.